Steroidal mineralocorticoid-receptor-antagonists (MRAs), such as spironolactone and
eplerenone, are guideline-directed therapies in patients with heart failure with reduced …

Hypertension is very common and remains often poorly controlled in patients with chronic
kidney disease (CKD). Accurate blood pressure (BP) measurement is the essential first step …

This article is published as part of a supplement sponsored by Kidney Disease: Improving
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …

Background Renin-angiotensin-system inhibitors (RASi), that include angiotensin converting
enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) reduce proteinuria …

Objectives To evaluate the comparative effectiveness of sodium-glucose cotransporter-2
(SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl …

Concerns about hyperkalemia may result in the under-utilization of established and novel
therapies that improve kidney and/or cardiovascular outcomes in patients with type 2 …

Hyperkalemia (HK) is a life-threatening condition that often occurs in patients with chronic
kidney disease (CKD). High serum potassium (sKsK) is responsible for a higher risk of end …

Although renin–angiotensin system (RAS) inhibitors reduce the risk of cardiovascular
diseases and end-stage kidney disease (ESKD) in chronic kidney disease (CKD) patients …

Chronic kidney disease (CKD) is a health problem that is constantly growing. This disease
presents a diverse symptomatology that implies complex therapeutic management. One of …

Increasing potassium intake ameliorates blood pressure (BP) and cardiovascular (CV)
prognoses in the general population; therefore the World Health Organization recommends …